{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:00:40Z","timestamp":1793037640009,"version":"4.5.0"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-120"],"award-info":[{"award-number":["2022-PUMCH-B-120"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-D-002"],"award-info":[{"award-number":["2022-PUMCH-D-002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00415-025-12992-7","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T10:43:13Z","timestamp":1741171393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Antibody-positive paraneoplastic neurological syndromes associated with immune checkpoint inhibitors: a systematic review"],"prefix":"10.1007","volume":"272","author":[{"given":"Le","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhi","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"12992_CR1","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1136\/jnnp.2004.038489","volume":"75","author":"JE Greenlee","year":"2004","unstructured":"Greenlee JE (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75:1090. https:\/\/doi.org\/10.1136\/jnnp.2004.038489","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12992_CR2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001014","author":"F Graus","year":"2021","unstructured":"Graus F, Vogrig A, Mu\u00f1iz-Castrillo S, Antoine JCG, Desestret V, Dubey D, Giometto B, Irani SR, Joubert B, Leypoldt F, McKeon A, Pr\u00fcss H, Psimaras D, Thomas L, Titulaer MJ, Vedeler CA, Verschuuren JJ, Dalmau J, Honnorat J (2021) Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000001014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12992_CR3","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1056\/NEJMra023009","volume":"349","author":"RB Darnell","year":"2003","unstructured":"Darnell RB, Posner JB (2003) Paraneoplastic syndromes involving the nervous system. N Engl J Med 349:1543\u20131554. https:\/\/doi.org\/10.1056\/NEJMra023009","journal-title":"N Engl J Med"},{"key":"12992_CR4","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000883","author":"J H\u00e9bert","year":"2020","unstructured":"H\u00e9bert J, Riche B, Vogrig A, Mu\u00f1iz-Castrillo S, Joubert B, Picard G, Rogemond V, Psimaras D, Alentorn A, Berzero G, Desestret V, Rabilloud M, Honnorat J (2020) Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/nxi.0000000000000883","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12992_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11060-018-03053-3","volume":"141","author":"AM Chan","year":"2019","unstructured":"Chan AM, Baehring JM (2019) Paraneoplastic neurological syndromes: a single institution 10-year case series. J Neurooncol 141:431\u2013439. https:\/\/doi.org\/10.1007\/s11060-018-03053-3","journal-title":"J Neurooncol"},{"key":"12992_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103105","author":"L Lorusso","year":"2020","unstructured":"Lorusso L, Precone V, Ferrari D, Ngonga GK, Russo AG, Paolacci S, Bertelli M (2020) Paraneoplastic neurological syndromes: study of prevalence in a province of the Lombardy Region, Italy. J Clin Med. https:\/\/doi.org\/10.3390\/jcm9103105","journal-title":"J Clin Med"},{"key":"12992_CR7","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1001\/archneurol.2009.341","volume":"67","author":"B Giometto","year":"2010","unstructured":"Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G (2010) Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol 67:330\u2013335. https:\/\/doi.org\/10.1001\/archneurol.2009.341","journal-title":"Arch Neurol"},{"key":"12992_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11060-015-1898-7","volume":"125","author":"MA Kanikannan","year":"2015","unstructured":"Kanikannan MA, Sirisha Y, Uppin MS, Jabeen SA, Kandadai RM, Sundaram C, Raghunadharao D, Borgohain R (2015) Incidence and spectrum of paraneoplastic neurological syndromes: single center study. J Neurooncol 125:197\u2013206. https:\/\/doi.org\/10.1007\/s11060-015-1898-7","journal-title":"J Neurooncol"},{"key":"12992_CR9","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, Herbrich SM, Anandhan S, Islam S, Amit M, Anandappa G, Allison JP (2023) Immune checkpoint therapy-current perspectives and future directions. Cell 186:1652\u20131669. https:\/\/doi.org\/10.1016\/j.cell.2023.03.006","journal-title":"Cell"},{"key":"12992_CR10","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"12992_CR11","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nrneurol.2017.144","volume":"13","author":"LM Yshii","year":"2017","unstructured":"Yshii LM, Hohlfeld R, Liblau RS (2017) Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat Rev Neurol 13:755\u2013763. https:\/\/doi.org\/10.1038\/nrneurol.2017.144","journal-title":"Nat Rev Neurol"},{"key":"12992_CR12","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/wnl.0000000000011795","volume":"96","author":"A Marini","year":"2021","unstructured":"Marini A, Bernardini A, Gigli GL, Valente M, Mu\u00f1iz-Castrillo S, Honnorat J, Vogrig A (2021) Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology 96:754\u2013766. https:\/\/doi.org\/10.1212\/wnl.0000000000011795","journal-title":"Neurology"},{"key":"12992_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/s1474-4422(23)00369-1","volume":"23","author":"A Farina","year":"2024","unstructured":"Farina A, Villagr\u00e1n-Garc\u00eda M, Vogrig A, Zekeridou A, Mu\u00f1iz-Castrillo S, Velasco R, Guidon AC, Joubert B, Honnorat J (2024) Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes. Lancet Neurol 23:81\u201394. https:\/\/doi.org\/10.1016\/s1474-4422(23)00369-1","journal-title":"Lancet Neurol"},{"key":"12992_CR14","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000604","author":"A Vogrig","year":"2019","unstructured":"Vogrig A, Fouret M, Joubert B, Picard G, Rogemond V, Pinto AL, Mu\u00f1iz-Castrillo S, Roger M, Raimbourg J, Dayen C, Grignou L, Pallix-Guyot M, Lannoy J, Ducray F, Desestret V, Psimaras D, Honnorat J (2019) Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/nxi.0000000000000604","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12992_CR15","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200058","author":"A Farina","year":"2023","unstructured":"Farina A, Villagr\u00e1n-Garc\u00eda M, Ciano-Petersen NL, Vogrig A, Mu\u00f1iz-Castrillo S, Taillandier L, Michaud M, Lefilliatre M, Wang A, Lepine Z, Picard G, Wucher V, Dhairi M, Fabien N, Goncalves D, Rogemond V, Joubert B, Honnorat J (2023) Anti-Hu antibodies in patients with neurologic side effects of immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/nxi.0000000000200058","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12992_CR16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","volume":"16","author":"F Graus","year":"2019","unstructured":"Graus F, Dalmau J (2019) Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 16:535\u2013548. https:\/\/doi.org\/10.1038\/s41571-019-0194-4","journal-title":"Nat Rev Clin Oncol"},{"key":"12992_CR17","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1007\/s13311-022-01184-0","volume":"19","author":"SL Duong","year":"2022","unstructured":"Duong SL, Pr\u00fcss H (2022) Paraneoplastic autoimmune neurological syndromes and the role of immune checkpoint inhibitors. Neurotherapeutics 19:848\u2013863. https:\/\/doi.org\/10.1007\/s13311-022-01184-0","journal-title":"Neurotherapeutics"},{"key":"12992_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jns.2015.01.028","volume":"350","author":"A Vogrig","year":"2015","unstructured":"Vogrig A, Ferrari S, Tinazzi M, Manganotti P, Vattemi G, Monaco S (2015) Anti-Ma-associated encephalomyeloradiculopathy in a patient with pleural mesothelioma. J Neurol Sci 350:105\u2013106. https:\/\/doi.org\/10.1016\/j.jns.2015.01.028","journal-title":"J Neurol Sci"},{"key":"12992_CR19","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1001\/jamaneurol.2016.1399","volume":"73","author":"TJ Williams","year":"2016","unstructured":"Williams TJ, Benavides DR, Patrice KA, Dalmau JO, De \u00c1vila ALR, Le DT, Lipson EJ, Probasco JC, Mowry EM (2016) Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 73:928\u2013933. https:\/\/doi.org\/10.1001\/jamaneurol.2016.1399","journal-title":"JAMA Neurol"},{"key":"12992_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.lungcan.2017.05.002","volume":"109","author":"J Raskin","year":"2017","unstructured":"Raskin J, Masrori P, Cant A, Snoeckx A, Hiddinga B, Kohl S, Janssens A, Cras P, Van Meerbeeck JP (2017) Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody. Lung Cancer 109:74\u201377. https:\/\/doi.org\/10.1016\/j.lungcan.2017.05.002","journal-title":"Lung Cancer"},{"key":"12992_CR21","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000439","volume":"5","author":"AF Hottinger","year":"2018","unstructured":"Hottinger AF, de Micheli R, Guido V, Karampera A, Hagmann P, Du Pasquier R (2018) Natalizumab may control immune checkpoint inhibitor-induced limbic encephalitis. Neurol Neuroimmunol Neuroinflamm 5:e439. https:\/\/doi.org\/10.1212\/nxi.0000000000000439","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12992_CR22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11060-018-2752-5","volume":"137","author":"A Fellner","year":"2018","unstructured":"Fellner A, Makranz C, Lotem M, Bokstein F, Taliansky A, Rosenberg S, Blumenthal DT, Mandel J, Fichman S, Kogan E, Steiner I, Siegal T, Lossos A, Yust-Katz S (2018) Neurologic complications of immune checkpoint inhibitors. J Neurooncol 137:601\u2013609. https:\/\/doi.org\/10.1007\/s11060-018-2752-5","journal-title":"J Neurooncol"},{"key":"12992_CR23","doi-asserted-by":"publisher","first-page":"e597","DOI":"10.1016\/j.cllc.2018.04.009","volume":"19","author":"H Matsuoka","year":"2018","unstructured":"Matsuoka H, Kimura H, Koba H, Tambo Y, Ohkura N, Hara J, Sone T, Kasahara K (2018) Nivolumab-induced limbic encephalitis with anti-hu antibody in a patient with advanced pleomorphic carcinoma of the lung. Clin Lung Cancer 19:e597\u2013e599. https:\/\/doi.org\/10.1016\/j.cllc.2018.04.009","journal-title":"Clin Lung Cancer"},{"key":"12992_CR24","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s13256-018-1786-9","volume":"12","author":"J Kopeck\u00fd","year":"2018","unstructured":"Kopeck\u00fd J, Kube\u010dek O, Geryk T, Slov\u00e1\u010dkov\u00e1 B, Hoffmann P, \u017diaran M, Priester P (2018) Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report. J Med Case Rep 12:262. https:\/\/doi.org\/10.1186\/s13256-018-1786-9","journal-title":"J Med Case Rep"},{"key":"12992_CR25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1634\/theoncologist.2017-0344","volume":"23","author":"KP Papadopoulos","year":"2018","unstructured":"Papadopoulos KP, Romero RS, Gonzalez G, Dix JE, Lowy I, Fury M (2018) Anti-hu-associated autoimmune limbic encephalitis in a patient with PD-1 inhibitor-responsive myxoid chondrosarcoma. Oncologist 23:118\u2013120. https:\/\/doi.org\/10.1634\/theoncologist.2017-0344","journal-title":"Oncologist"},{"key":"12992_CR26","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.90.15_supplement.P5.409","author":"B Santomasso","year":"2018","unstructured":"Santomasso B, D\u2019Angelo S (2018) Anti-CRMP5-associated paraneoplastic neurologic syndrome developing in a patient with metastatic merkel cell carcinoma during immune checkpoint inhibitor treatment. Neurology. https:\/\/doi.org\/10.1212\/WNL.90.15_supplement.P5.409","journal-title":"Neurology"},{"key":"12992_CR27","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000494078","volume":"10","author":"Y Nakatani","year":"2018","unstructured":"Nakatani Y, Tanaka N, Enami T, Minami S, Okazaki T, Komuta K (2018) Lambert-Eaton myasthenic syndrome caused by nivolumab in a patient with squamous cell lung cancer. Case Rep Neurol 10:346\u2013352. https:\/\/doi.org\/10.1159\/000494078","journal-title":"Case Rep Neurol"},{"key":"12992_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.576980","volume":"334","author":"A Gill","year":"2019","unstructured":"Gill A, Perez MA, Perrone CM, Bae CJ, Pruitt AA, Lancaster E (2019) A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes. J Neuroimmunol 334:576980. https:\/\/doi.org\/10.1016\/j.jneuroim.2019.576980","journal-title":"J Neuroimmunol"},{"key":"12992_CR29","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000000105","author":"JA Cerra-Franco","year":"2019","unstructured":"Cerra-Franco JA, Fernandez-Cruz C, Estremera-Marcial R, Pagan-Torres H, Martinez-Souss J, Toro DH (2019) Anti-Hu-mediated paraneoplastic chronic intestinal pseudo-obstruction arising from small cell prostate cancer. ACG Case Rep J. https:\/\/doi.org\/10.14309\/crj.0000000000000105","journal-title":"ACG Case Rep J"},{"key":"12992_CR30","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s13760-019-01179-3","volume":"120","author":"J Leempoel","year":"2020","unstructured":"Leempoel J, Ruyssen A, Kessler R, Van Pesch V, Gille M (2020) Anti-Ma2\/Ta paraneoplastic rhombencephalitis in a patient with lung cancer responsive to anti-PD1 therapy. Acta Neurol Belg 120:451\u2013452. https:\/\/doi.org\/10.1007\/s13760-019-01179-3","journal-title":"Acta Neurol Belg"},{"key":"12992_CR31","doi-asserted-by":"publisher","first-page":"5353202","DOI":"10.1155\/2019\/5353202","volume":"2019","author":"K Agrawal","year":"2019","unstructured":"Agrawal K, Agrawal N (2019) Lambert-Eaton Myasthenic syndrome secondary to Nivolumab and Ipilimumab in a patient with small-cell lung cancer. Case Rep Neurol Med 2019:5353202. https:\/\/doi.org\/10.1155\/2019\/5353202","journal-title":"Case Rep Neurol Med"},{"key":"12992_CR32","doi-asserted-by":"publisher","first-page":"e174","DOI":"10.1016\/j.jtho.2019.03.017","volume":"14","author":"P Du Rusquec","year":"2019","unstructured":"Du Rusquec P, Peyre A, Toulgoat F, Honnorat J, Raimbourg J (2019) Fatal Anti-Ma2 encephalitis related to treatment of malignant pleural mesothelioma with a combination of anti-programmed death 1 and anti-cytotoxic T-Lymphocyte associated protein 4 antibodies. J Thorac Oncol 14:e174\u2013e176. https:\/\/doi.org\/10.1016\/j.jtho.2019.03.017","journal-title":"J Thorac Oncol"},{"key":"12992_CR33","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/jjco\/hyz087","volume":"49","author":"R Shibaki","year":"2019","unstructured":"Shibaki R, Murakami S, Oki K, Ohe Y (2019) Nivolumab-induced autoimmune encephalitis in an anti-neuronal autoantibody-positive patient. Jpn J Clin Oncol 49:793\u2013794. https:\/\/doi.org\/10.1093\/jjco\/hyz087","journal-title":"Jpn J Clin Oncol"},{"key":"12992_CR34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s40425-019-0727-5","volume":"7","author":"N Shah","year":"2019","unstructured":"Shah N, Jacob J, Househ Z, Shiner E, Baird L, Soudy H (2019) Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab. J Immunother Cancer 7:247. https:\/\/doi.org\/10.1186\/s40425-019-0727-5","journal-title":"J Immunother Cancer"},{"key":"12992_CR35","doi-asserted-by":"publisher","first-page":"E18","DOI":"10.1002\/mus.27141","volume":"63","author":"AJ Gill","year":"2021","unstructured":"Gill AJ, Gandhy S, Lancaster E (2021) Nivolumab-associated Lambert-Eaton myasthenic syndrome and cerebellar dysfunction in a patient with a neuroendocrine tumor. Muscle Nerve 63:E18-e21. https:\/\/doi.org\/10.1002\/mus.27141","journal-title":"Muscle Nerve"},{"key":"12992_CR36","doi-asserted-by":"publisher","first-page":"E2442","DOI":"10.1212\/WNL.0000000000010632","volume":"95","author":"E Sechi","year":"2020","unstructured":"Sechi E, Markovic SN, McKeon A, Dubey D, Liewluck T, Lennon VA, Lopez-Chiriboga AS, Klein CJ, Mauermann M, Pittock SJ, Flanagan EP, Zekeridou A (2020) Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes. Neurology 95:E2442\u2013E2452. https:\/\/doi.org\/10.1212\/WNL.0000000000010632","journal-title":"Neurology"},{"key":"12992_CR37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/cji.0000000000000314","volume":"43","author":"K Kang","year":"2020","unstructured":"Kang K, Zheng K, Zhang Y (2020) Paraneoplastic encephalitis and enteric neuropathy associated with anti-hu antibody in a patient following immune-checkpoint inhibitor therapy. J Immunother 43:165\u2013168. https:\/\/doi.org\/10.1097\/cji.0000000000000314","journal-title":"J Immunother"},{"key":"12992_CR38","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/ene.14251","volume":"27","author":"N Mongay Ochoa","year":"2020","unstructured":"Mongay Ochoa N, Vogrig A, Mu\u00f1iz Castrillo S, Honnorat J (2020) Anti-Hu-associated paraneoplastic syndromes triggered by immunecheckpoint inhibitor treatment. Eur J Neurol 27:1170. https:\/\/doi.org\/10.1111\/ene.14251","journal-title":"Eur J Neurol"},{"key":"12992_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2019.12.074","volume":"131","author":"J Philipps","year":"2020","unstructured":"Philipps J, Mann S, Marckmann- Boenke S, Schellinger P (2020) Inflammatory anti- Hu positive demyelinating neuropathy induced by Checkpoint inhibitors Nivolumab and Ipilimumab. Clin Neurophysiol 131:e214. https:\/\/doi.org\/10.1016\/j.clinph.2019.12.074","journal-title":"Clin Neurophysiol"},{"key":"12992_CR40","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1212\/WNL.94.15_supplement.1230","volume":"94","author":"P Raibagkar","year":"2020","unstructured":"Raibagkar P, Ho D, Gunturu K, Srinivasan J (2020) Worsening of anti-hu paraneoplastic neurological syndrome related to anti-PD-1 treatment: case report and literature review. Neurology 94:1230","journal-title":"Neurology"},{"key":"12992_CR41","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1136\/practneurol-2019-002464","volume":"20","author":"S Lyons","year":"2020","unstructured":"Lyons S, Joyce R, Moynagh P, O\u2019Donnell L, Blazkova S, Counihan TJ (2020) Autoimmune encephalitis associated with Ma2 antibodies and immune checkpoint inhibitor therapy. Pract Neurol 20:256\u2013259. https:\/\/doi.org\/10.1136\/practneurol-2019-002464","journal-title":"Pract Neurol"},{"key":"12992_CR42","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.4889-20","author":"S Tatsumi","year":"2020","unstructured":"Tatsumi S, Uryu K, Iwasaki S, Harada H (2020) A case of anti-CRMP5 paraneoplastic neurological syndrome induced by atezolizumab for small cell lung cancer. Intern Med. https:\/\/doi.org\/10.2169\/internalmedicine.4889-20","journal-title":"Intern Med"},{"key":"12992_CR43","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s13760-020-01564-3","volume":"121","author":"G Abbadessa","year":"2021","unstructured":"Abbadessa G, Miele G, Fratta M, Bonavita S (2021) Paraneoplastic syndrome or immune-related adverse event? A case of rhomboencephalitis in a patient treated with Pembrolizumab. Acta Neurol Belg 121:1341\u20131342. https:\/\/doi.org\/10.1007\/s13760-020-01564-3","journal-title":"Acta Neurol Belg"},{"key":"12992_CR44","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.1007\/s10072-021-05557-9","volume":"42","author":"A Duplaine","year":"2021","unstructured":"Duplaine A, Prot C, Le-Masson G, Soulages A, Duval F, Dutriaux C, Prey S (2021) Myasthenia Gravis Lambert-Eaton overlap syndrome induced by nivolumab in a metastatic melanoma patient. Neurol Sci 42:5377\u20135378. https:\/\/doi.org\/10.1007\/s10072-021-05557-9","journal-title":"Neurol Sci"},{"key":"12992_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2021.101525","volume":"34","author":"K Nakashima","year":"2021","unstructured":"Nakashima K, Fujii Y, Sato M, Igarashi K, Kobayashi M, Ishizuka T (2021) A case of non-small cell lung cancer presenting anti-amphiphysin antibody-positive paraneoplastic neurological syndrome. Respir Med Case Rep 34:101525. https:\/\/doi.org\/10.1016\/j.rmcr.2021.101525","journal-title":"Respir Med Case Rep"},{"key":"12992_CR46","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.2147\/ott.S337331","volume":"14","author":"J Li","year":"2021","unstructured":"Li J, Jiang J, Lv J, Zhang R, Chen W, Li S, Jin Q, Wang G (2021) Anti-\u03b3-Aminobutyric Acid Type \u03b2 Receptor Antibody-Associated Encephalitis After 2 Cycles of Durvalumab Therapy in a Patient with Small Cell Lung Cancer: A Case Report. Onco Targets Ther 14:5227\u20135236. https:\/\/doi.org\/10.2147\/ott.S337331","journal-title":"Onco Targets Ther"},{"key":"12992_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.118843","author":"M Hardwick","year":"2021","unstructured":"Hardwick M, Nolan L, Nicoll J, Jogai S, Arriola E, Joseph-Pietras D, Ottensmeier C, Galea I (2021) CD8 T cell-mediated cerebellitis directed against Purkinje cell antigen after ipilimumab for small cell lung cancer. J Neurol Sci. https:\/\/doi.org\/10.1016\/j.jns.2021.118843","journal-title":"J Neurol Sci"},{"key":"12992_CR48","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.psym.2020.08.011","volume":"62","author":"N Yordduangjun","year":"2021","unstructured":"Yordduangjun N, Dishion E, McKnight CA, Caplan JP (2021) Immune checkpoint inhibitor-associated autoimmune encephalitis. J Acad Consult Liaison Psychiatry 62:115\u2013118. https:\/\/doi.org\/10.1016\/j.psym.2020.08.011","journal-title":"J Acad Consult Liaison Psychiatry"},{"key":"12992_CR49","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1159\/000519763","volume":"13","author":"R Hashimoto","year":"2021","unstructured":"Hashimoto R, Tanabe E, Otsuka Y, Yoneda Y, Kageyama Y (2021) Anti-Ma2-associated limbic encephalitis after termination of immune checkpoint inhibitor therapy for malignant pleural mesothelioma. Case Rep Neurol 13:724\u2013728. https:\/\/doi.org\/10.1159\/000519763","journal-title":"Case Rep Neurol"},{"key":"12992_CR50","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11060-021-03695-w","volume":"152","author":"SL Duong","year":"2021","unstructured":"Duong SL, Barbiero FJ, Nowak RJ, Baehring JM (2021) Neurotoxicities associated with immune checkpoint inhibitor therapy. J Neurooncol 152:265\u2013277. https:\/\/doi.org\/10.1007\/s11060-021-03695-w","journal-title":"J Neurooncol"},{"key":"12992_CR51","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.2169\/internalmedicine.5629-20","volume":"60","author":"T Morimoto","year":"2021","unstructured":"Morimoto T, Orihashi T, Yamasaki K, Tahara M, Kato K, Yatera K (2021) Paraneoplastic sensory polyneuropathy related to Anti-PD-L1-including anticancer treatment in a patient with lung cancer. Intern Med 60:1577\u20131581. https:\/\/doi.org\/10.2169\/internalmedicine.5629-20","journal-title":"Intern Med"},{"key":"12992_CR52","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.21037\/tlcr-21-222","volume":"10","author":"V Albarr\u00e1n","year":"2021","unstructured":"Albarr\u00e1n V, Pozas J, Rodr\u00edguez F, Carrasco \u00c1, Corral E, Lage Y, \u00c1lvarez-Ballesteros P, Soria A, Garrido P (2021) Acute anti-Ma2 paraneoplastic encephalitis associated to pembrolizumab: a case report and review of literature. Transl Lung Cancer Res 10:3303\u20133311. https:\/\/doi.org\/10.21037\/tlcr-21-222","journal-title":"Transl Lung Cancer Res"},{"key":"12992_CR53","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/cji.0000000000000362","volume":"44","author":"Y Shechtman","year":"2021","unstructured":"Shechtman Y, Shalata W, Khoury R, Mahajna A, Weller B, Agbarya A (2021) Encephalitis induced by durvalumab during treatment of metastatic small-cell lung cancer: illustrative case and review of the literature. J Immunother 44:243\u2013247. https:\/\/doi.org\/10.1097\/cji.0000000000000362","journal-title":"J Immunother"},{"key":"12992_CR54","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1212\/01.wnl.0000903616.08384.e6","volume":"93","author":"A Al Moamen","year":"2022","unstructured":"Al Moamen A, Del Pilar Guillermo M, Prieto Eibl O, Carbunar LT, Detyniecki K (2022) Concurrent autoimmune encephalitis, diabetes, and thyroiditis after a single dose of Pembrolizumab. Neurology 93:S46. https:\/\/doi.org\/10.1212\/01.wnl.0000903616.08384.e6","journal-title":"Neurology"},{"key":"12992_CR55","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.2169\/internalmedicine.8387-21","volume":"61","author":"E Kunii","year":"2022","unstructured":"Kunii E, Owaki S, Yamada K, Yoshihara M, Yamaba Y, Takakuwa O, Toyoda T, Akita K (2022) Lambert-eaton myasthenic syndrome caused by atezolizumab in a patient with small-cell lung cancer. Intern Med 61:1739\u20131742. https:\/\/doi.org\/10.2169\/internalmedicine.8387-21","journal-title":"Intern Med"},{"key":"12992_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12060773","author":"Y Gao","year":"2022","unstructured":"Gao Y, Pan J, Shen D, Peng L, Mao Z, Wang C, Meng H, Zhou Q, Chen S (2022) Immune checkpoint inhibitor associated autoimmune encephalitis, rare and novel topic of neuroimmunology: a case report and review of the literature. Brain Sci. https:\/\/doi.org\/10.3390\/brainsci12060773","journal-title":"Brain Sci"},{"key":"12992_CR57","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2169\/internalmedicine.7167-21","volume":"61","author":"H Arai","year":"2022","unstructured":"Arai H, Utsu Y, Horio J, Furukawa S, Kikkawa Y (2022) Paraneoplastic Opsoclonus-myoclonus Syndrome with Anti-Hu and Anti-SOX-1 antibodies after immune-checkpoint inhibitor treatment combined with chemotherapy in a patient with small-cell lung cancer. Intern Med 61:71\u201374. https:\/\/doi.org\/10.2169\/internalmedicine.7167-21","journal-title":"Intern Med"},{"key":"12992_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.nerep.2022.100116","author":"K Abusamra","year":"2022","unstructured":"Abusamra K, Thandampallayam M, Lukins D, Sudhakar P (2022) Stiff Person Syndrome in a patient with atypical carcinoid tumor of the lung secondary to anti-amphiphysin antibodies: a case report and literature review. Neuroimmunol Rep. https:\/\/doi.org\/10.1016\/j.nerep.2022.100116","journal-title":"Neuroimmunol Rep"},{"key":"12992_CR59","doi-asserted-by":"publisher","first-page":"9290922","DOI":"10.1155\/2022\/9290922","volume":"2022","author":"K Nakashima","year":"2022","unstructured":"Nakashima K, Demura Y, Kurokawa K, Takeda T, Jikuya N, Oi M, Tada T, Akai M, Ishizuka T (2022) Immune checkpoint inhibitor-induced limbic encephalitis during treatment with Atezolizumab in a patient with small-cell lung cancer: a case report and review of the literature. Case Reports Immunol 2022:9290922. https:\/\/doi.org\/10.1155\/2022\/9290922","journal-title":"Case Reports Immunol"},{"key":"12992_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-247676","author":"L Laderman","year":"2022","unstructured":"Laderman L, Naveed O, LoPinto-Khoury C, Dotan E, Miron B (2022) Paraneoplastic limbic encephalitis following treatment with single-agent pembrolizumab for advanced gastroesophageal adenocarcinoma. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2021-247676","journal-title":"BMJ Case Rep"},{"key":"12992_CR61","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1212\/WNL.98.18_supplement.111","volume":"98","author":"M Tariq","year":"2022","unstructured":"Tariq M, Obrien B (2022) Unusual presentation of paraneoplastic LimbicEncephalitis (PLE) with Acute retrogradeamnesia as presenting symptom. Neurol 98:111","journal-title":"Neurol"},{"key":"12992_CR62","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1136\/jnnp-2021-326369","volume":"93","author":"P Chompoopong","year":"2022","unstructured":"Chompoopong P, Zekeridou A, Shelly S, Ruff M, Dyck PJ, Klein CJ, Pittock SJ, Mauermann M, Dubey D (2022) Comparison of immune checkpoint inhibitor-related neuropathies among patients with neuroendocrine and non-neuroendocrine tumours. J Neurol Neurosurg Psychiatry 93:112\u2013114. https:\/\/doi.org\/10.1136\/jnnp-2021-326369","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12992_CR63","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/pcn.13325","volume":"76","author":"S Wada","year":"2022","unstructured":"Wada S, Iwamoto K, Ozaki N (2022) Atezolizumab, an immune checkpoint inhibitor, caused precedent depressive symptoms related to limbic encephalitis. Psychiatry Clin Neurosci 76:125\u2013126. https:\/\/doi.org\/10.1111\/pcn.13325","journal-title":"Psychiatry Clin Neurosci"},{"key":"12992_CR64","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10637-021-01154-x","volume":"40","author":"L Wang","year":"2022","unstructured":"Wang L, Lou H, Li B, Li J, Yang YM (2022) Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer. Invest New Drugs 40:151\u2013156. https:\/\/doi.org\/10.1007\/s10637-021-01154-x","journal-title":"Invest New Drugs"},{"key":"12992_CR65","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s12311-021-01298-9","volume":"21","author":"Y Segal","year":"2022","unstructured":"Segal Y, Bukstein F, Raz M, Aizenstein O, Alcalay Y, Gadoth A (2022) PD-1-inhibitor-induced PCA-2 (MAP1B) Autoimmunity in a patient with renal cell carcinoma. Cerebellum 21:328\u2013331. https:\/\/doi.org\/10.1007\/s12311-021-01298-9","journal-title":"Cerebellum"},{"key":"12992_CR66","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.2648-23","author":"A Saitou","year":"2023","unstructured":"Saitou A, Shioya M, Nagahisa Y, Haseyama A, Niwa R, Tsuchimoto J, Chiba H (2023) Small-cell lung carcinoma with gastrointestinal pseudo-obstruction as a paraneoplastic neurological syndrome elicited by an immune checkpoint inhibitor. Intern Med. https:\/\/doi.org\/10.2169\/internalmedicine.2648-23","journal-title":"Intern Med"},{"key":"12992_CR67","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/10815589231189337","volume":"71","author":"DW Choi","year":"2023","unstructured":"Choi DW, Bag A, Eilava S, Agadi S, Janosky M, Patel D (2023) Delayed Onconeuronal antibody development in immune checkpoint inhibitor induced Paraneoplastimc syndrome. J Investig Med 71:142\u2013143. https:\/\/doi.org\/10.1177\/10815589231189337","journal-title":"J Investig Med"},{"key":"12992_CR68","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1111\/ene.15835","volume":"30","author":"C Valencia-Sanchez","year":"2023","unstructured":"Valencia-Sanchez C, Sechi E, Dubey D, Flanagan EP, McKeon A, Pittock SJ, Zekeridou A (2023) Immune checkpoint inhibitor-associated central nervous system autoimmunity. Eur J Neurol 30:2418\u20132429. https:\/\/doi.org\/10.1111\/ene.15835","journal-title":"Eur J Neurol"},{"key":"12992_CR69","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-023-01601-w","author":"G Vaghi","year":"2023","unstructured":"Vaghi G, Vegezzi E, Bini P, Gastaldi M, Diamanti L, Marchioni E, Colnaghi S (2023) A case of Anti-Ma2 encephalitis presenting with pendular torsional nystagmus. Cerebellum. https:\/\/doi.org\/10.1007\/s12311-023-01601-w","journal-title":"Cerebellum"},{"key":"12992_CR70","doi-asserted-by":"publisher","first-page":"1278761","DOI":"10.3389\/fimmu.2023.1278761","volume":"14","author":"TT Moss","year":"2023","unstructured":"Moss TT, Stavem K, Aandahl A, Gl\u00f8ersen AS, Gr\u00f8nberg BH, Neumann K, Vedeler CA, Lundqvist C (2023) Case report: limbic encephalitis following treatment with durvalumab for small-cell lung cancer. Front Immunol 14:1278761. https:\/\/doi.org\/10.3389\/fimmu.2023.1278761","journal-title":"Front Immunol"},{"key":"12992_CR71","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.1771-23","author":"T Seki","year":"2023","unstructured":"Seki T, Baba K, Hayashi T, Furuta R, Hirosawa H, Mitsui T, Maesaka H, Takasawa S, Miwa T, Tanaka K, Nakatsuji Y (2023) A case of lung cancer wherein durvalumab induced both anti-CRMP-5 antibody-related paraneoplastic neurological syndromes and neurological adverse events. Intern Med. https:\/\/doi.org\/10.2169\/internalmedicine.1771-23","journal-title":"Intern Med"},{"key":"12992_CR72","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.2169\/internalmedicine.0072-22","volume":"62","author":"Y Takigawa","year":"2023","unstructured":"Takigawa Y, Watanabe H, Omote Y, Kurihara S, Inoue T, Fujiwara M, Mitsumune S, Onishi K, Kudo K, Sato A, Sato K, Fujiwara K, Shibayama T (2023) Lambert-Eaton Myasthenic syndrome recurrence induced by Pembrolizumab in a patient with non-small-cell lung cancer. Intern Med 62:1055\u20131058. https:\/\/doi.org\/10.2169\/internalmedicine.0072-22","journal-title":"Intern Med"},{"key":"12992_CR73","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1111\/1759-7714.14933","volume":"14","author":"Y Iwanaga","year":"2023","unstructured":"Iwanaga Y, Kawaguchi T, Yamasaki K, Sato T, Kubo N, Morimoto T, Isoshima Y, Sasahara Y, Orihashi T, Yatera K (2023) Fatal limbic encephalitis as paraneoplastic neurological syndrome in a patient with lung adenocarcinoma positive for Antiamphiphysin antibody after durvalumab treatment. Thorac Cancer 14:1899\u20131903. https:\/\/doi.org\/10.1111\/1759-7714.14933","journal-title":"Thorac Cancer"},{"key":"12992_CR74","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000203306","author":"K Zahra","year":"2023","unstructured":"Zahra K, Ahmed N, Sivakumar D, Mendoza EU, Veerappan V (2023) Anti-Ma2 antibody paraneoplastic cerebellar degeneration associated with renal cell carcinoma: a case report. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000203306","journal-title":"Neurology"},{"key":"12992_CR75","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jneuroim.2016.12.016","volume":"305","author":"MP Brown","year":"2017","unstructured":"Brown MP, Hissaria P, Hsieh AH, Kneebone C, Vallat W (2017) Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy. J Neuroimmunol 305:16\u201318. https:\/\/doi.org\/10.1016\/j.jneuroim.2016.12.016","journal-title":"J Neuroimmunol"},{"key":"12992_CR76","doi-asserted-by":"publisher","first-page":"2548528","DOI":"10.1155\/2018\/2548528","volume":"2018","author":"S Shah","year":"2018","unstructured":"Shah S, Dunn-Pirio A, Luedke M, Morgenlander J, Skeen M, Eckstein C (2018) Nivolumab-induced autoimmune encephalitis in two patients with lung adenocarcinoma. Case Rep Neurol Med 2018:2548528. https:\/\/doi.org\/10.1155\/2018\/2548528","journal-title":"Case Rep Neurol Med"},{"key":"12992_CR77","first-page":"S134","volume":"60","author":"N Jiwa","year":"2019","unstructured":"Jiwa N, Lim-Fat MJ, Chukwueke U, Sands J, Doughty C (2019) Lambert-eaton myasthenic syndrome in the setting of immune heckpoint inhibitor treatment of small cell lung cancer. Muscle Nerve 60:S134","journal-title":"Muscle Nerve"},{"key":"12992_CR78","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1007\/s00259-020-04988-4","volume":"62","author":"C Anderson","year":"2020","unstructured":"Anderson C, Guidon A, Riehle C, Khan F, Kolb N (2020) Lambert eaton myasthenic syndrome in a patient with small cell lung cancer on immune checkpoint inhibitor therapy. Muscle Nerve 62:S47. https:\/\/doi.org\/10.1007\/s00259-020-04988-4","journal-title":"Muscle Nerve"},{"key":"12992_CR79","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00415-019-09666-6","volume":"267","author":"M Chung","year":"2020","unstructured":"Chung M, Jaffer M, Verma N, Mokhtari S, Ramsakal A, Peguero E (2020) Immune checkpoint inhibitor induced anti-glutamic acid decarboxylase 65 (Anti-GAD 65) limbic encephalitis responsive to intravenous immunoglobulin and plasma exchange. J Neurol 267:1023\u20131025. https:\/\/doi.org\/10.1007\/s00415-019-09666-6","journal-title":"J Neurol"},{"key":"12992_CR80","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s42466-020-00099-5","volume":"2","author":"MF Dohrn","year":"2020","unstructured":"Dohrn MF, Sch\u00f6ne U, K\u00fcppers C, Christen D, Schulz JB, Gess B, Tauber S (2020) Immunoglobulins to mitigate paraneoplastic Lambert Eaton Myasthenic Syndrome under checkpoint inhibition in Merkel cell carcinoma. Neurol Res Pract 2:52. https:\/\/doi.org\/10.1186\/s42466-020-00099-5","journal-title":"Neurol Res Pract"},{"key":"12992_CR81","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2019.4379","volume":"77","author":"A Kunchok","year":"2020","unstructured":"Kunchok A, Zekeridou A, Pittock S (2020) CRMP5-IgG-associated paraneoplastic myelopathy With PD-L1 inhibitor therapy. JAMA Neurol 77:255\u2013256. https:\/\/doi.org\/10.1001\/jamaneurol.2019.4379","journal-title":"JAMA Neurol"},{"key":"12992_CR82","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.1007\/s10072-021-05312-0","volume":"42","author":"GT Maniscalco","year":"2021","unstructured":"Maniscalco GT, Zekeridou A, Allegorico L, Ranieri A, Napolitano M, Pezzella M, Gatta LD, Manzo V, Ferrari S, Mariotto S (2021) GAD65 autoimmunity after treatment with nivolumab: a multifocal presentation. Neurol Sci 42:4289\u20134291. https:\/\/doi.org\/10.1007\/s10072-021-05312-0","journal-title":"Neurol Sci"},{"key":"12992_CR83","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/ene.14692","volume":"28","author":"J Piepgras","year":"2021","unstructured":"Piepgras J, M\u00fcller A, Steffen F, Lotz J, Loquai C, Zipp F, Dresel C, Bittner S (2021) Neurofilament light chain levels reflect outcome in a patient with glutamic acid decarboxylase 65 antibody-positive autoimmune encephalitis under immune checkpoint inhibitor therapy. Eur J Neurol 28:1086\u20131089. https:\/\/doi.org\/10.1111\/ene.14692","journal-title":"Eur J Neurol"},{"key":"12992_CR84","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1212\/WNL.98.18_supplement.3628","volume":"98","author":"YJ Choi","year":"2022","unstructured":"Choi YJ, Lomax J, Kong XT (2022) Acute onset, rapidly progressive anti-yo positive paraneoplastic cerebellar degeneration, associated with ovarian cancer, in the setting of immune check point inhibit or pembrolizumab use: a case report. Neurology 98:3628","journal-title":"Neurology"},{"key":"12992_CR85","doi-asserted-by":"publisher","first-page":"12801","DOI":"10.1182\/blood-2022-169197","volume":"140","author":"M Shan Ul Abedin","year":"2022","unstructured":"Shan Ul Abedin M, Khan M, Evoghlian F, Mehreen R (2022) Lambert eaton myasthenic syndrome (LEMS) secondary to Atezolizumab in a patient with squamous cell carcinoma of the lung. Blood 140:12801\u201312802. https:\/\/doi.org\/10.1182\/blood-2022-169197","journal-title":"Blood"},{"key":"12992_CR86","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/ene.15466","volume":"29","author":"B Wagner","year":"2022","unstructured":"Wagner B, Beuttler A, Kiriakidis N, Joerger M, Kaeufeler R, Hundsberger T (2022) Management of Lambert-Eaton Myasthenic Syndrome in the context of immunecheckpoint-inhibitor treatment - A Case Report. Eur J Neurol 29:482\u2013483. https:\/\/doi.org\/10.1111\/ene.15466","journal-title":"Eur J Neurol"},{"key":"12992_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.850540","volume":"13","author":"H Zhou","year":"2022","unstructured":"Zhou H, Xie X, Zhang T, Yang M, Zhou D, Yang T (2022) Anti-GAD65 antibody-associated autoimmune encephalitis with predominant cerebellar involvement following Toripalimab treatment: a case report of a novel irAE of Toripalimab. Front Immunol 13:850540. https:\/\/doi.org\/10.3389\/fimmu.2022.850540","journal-title":"Front Immunol"},{"key":"12992_CR88","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1017\/cjn.2022.71","volume":"50","author":"AA AlSabah","year":"2023","unstructured":"AlSabah AA, Altman R (2023) Nivolumab-induced limbic encephalitis associated with glutamic acid decarboxylase 65 antibodies. Can J Neurol Sci 50:635\u2013636. https:\/\/doi.org\/10.1017\/cjn.2022.71","journal-title":"Can J Neurol Sci"},{"key":"12992_CR89","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000204320","author":"J Purks","year":"2023","unstructured":"Purks J, Samkoff L (2023) Rare development of anti-CRMP5 Parkinsonism and worsening ataxia while on Atezolizumab for SCLC: a case report. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000204320","journal-title":"Neurology"},{"key":"12992_CR90","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000203728","author":"N Vorasoot","year":"2023","unstructured":"Vorasoot N, Halfdanarson TR, Madigan N, Thanarajasingam U, Zekeridou A (2023) Pre-existing Lambert-Eaton Myasthenic syndrome and scleroderma in a patient with neuroendocrine tumor undergoing immune checkpoint inhibitor cancer immunotherapy. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000203728","journal-title":"Neurology"},{"key":"12992_CR91","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.33557","volume":"15","author":"M Yamazoe","year":"2023","unstructured":"Yamazoe M, Hatakeyama T, Furukawa K, Kato K, Horiuchi K (2023) Atezolizumab-induced lambert-eaton myasthenic syndrome in a patient with small-cell lung cancer. Cureus 15:e33557. https:\/\/doi.org\/10.7759\/cureus.33557","journal-title":"Cureus"},{"key":"12992_CR92","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s43018-024-00730-3","volume":"5","author":"KPM Suijkerbuijk","year":"2024","unstructured":"Suijkerbuijk KPM, van Eijs MJM, van Wijk F, Eggermont AMM (2024) Clinical and translational attributes of immune-related adverse events. Nat Cancer 5:557\u2013571. https:\/\/doi.org\/10.1038\/s43018-024-00730-3","journal-title":"Nat Cancer"},{"key":"12992_CR93","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","volume":"7","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, Mammen A, Moslehi JJ, Salem JE (2019) Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer 7:134. https:\/\/doi.org\/10.1186\/s40425-019-0617-x","journal-title":"J Immunother Cancer"},{"key":"12992_CR94","doi-asserted-by":"publisher","first-page":"e1093","DOI":"10.1212\/wnl.0000000000008091","volume":"93","author":"D Dubey","year":"2019","unstructured":"Dubey D, David WS, Amato AA, Reynolds KL, Clement NF, Chute DF, Cohen JV, Lawrence DP, Mooradian MJ, Sullivan RJ, Guidon AC (2019) Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology 93:e1093\u2013e1103. https:\/\/doi.org\/10.1212\/wnl.0000000000008091","journal-title":"Neurology"},{"key":"12992_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, Lebbe C, Belin C, Ursu R, Carpentier AF (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73:1\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.001","journal-title":"Eur J Cancer"},{"key":"12992_CR96","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1001\/jamaoncol.2023.6277","volume":"10","author":"Y Tsukita","year":"2024","unstructured":"Tsukita Y, Tozuka T, Kushiro K, Hosokawa S, Sumi T, Uematsu M, Honjo O, Yamaguchi O, Asao T, Sugisaka J, Saito G, Shiihara J, Morita R, Katakura S, Yasuda T, Hisakane K, Miyauchi E, Morita S, Kobayashi K, Asahina H (2024) Immunotherapy or chemoimmunotherapy in older adults with advanced non-small cell lung cancer. JAMA Oncol 10:439\u2013447. https:\/\/doi.org\/10.1001\/jamaoncol.2023.6277","journal-title":"JAMA Oncol"},{"key":"12992_CR97","doi-asserted-by":"publisher","first-page":"e1677","DOI":"10.1212\/wnl.0000000000006435","volume":"91","author":"E Basal","year":"2018","unstructured":"Basal E, Zalewski N, Kryzer TJ, Hinson SR, Guo Y, Dubey D, Benarroch EE, Lucchinetti CF, Pittock SJ, Lennon VA, McKeon A (2018) Paraneoplastic neuronal intermediate filament autoimmunity. Neurology 91:e1677\u2013e1689. https:\/\/doi.org\/10.1212\/wnl.0000000000006435","journal-title":"Neurology"},{"key":"12992_CR98","doi-asserted-by":"publisher","first-page":"e815","DOI":"10.1212\/wnl.0000000000007971","volume":"93","author":"A Zekeridou","year":"2019","unstructured":"Zekeridou A, Kryzer T, Guo Y, Hassan A, Lennon V, Lucchinetti CF, Pittock S, McKeon A (2019) Phosphodiesterase 10A IgG: a novel biomarker of paraneoplastic neurologic autoimmunity. Neurology 93:e815\u2013e822. https:\/\/doi.org\/10.1212\/wnl.0000000000007971","journal-title":"Neurology"},{"key":"12992_CR99","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26943","author":"M Gilligan","year":"2024","unstructured":"Gilligan M, Lesnick CE, Guo Y, Bradshaw MJ, Ladha SS, Nowak M, Shah MP, Wittenborn JR, Basal E, Hinson S, Yang B, Dubey D, Mills JR, Pittock SJ, Zekeridou A, McKeon A (2024) Paraneoplastic calmodulin kinase-like vesicle-associated protein (CAMKV) autoimmune encephalitis. Ann Neurol. https:\/\/doi.org\/10.1002\/ana.26943","journal-title":"Ann Neurol"},{"key":"12992_CR100","doi-asserted-by":"publisher","first-page":"1108116","DOI":"10.3389\/fimmu.2023.1108116","volume":"14","author":"L M\u00fcller-Jensen","year":"2023","unstructured":"M\u00fcller-Jensen L, Knauss S, Ginesta Roque L, Schinke C, Maierhof SK, Bartels F, Finke C, Rentzsch K, Ulrich C, Mohr R, Stenzel W, Endres M, Boehmerle W, Huehnchen P (2023) Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events. Front Immunol 14:1108116. https:\/\/doi.org\/10.3389\/fimmu.2023.1108116","journal-title":"Front Immunol"},{"key":"12992_CR101","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1093\/brain\/awh203","volume":"127","author":"J Dalmau","year":"2004","unstructured":"Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, Saiz A, Meneses P, Rosenfeld MR (2004) Clinical analysis of anti-Ma2-associated encephalitis. Brain 127:1831\u20131844. https:\/\/doi.org\/10.1093\/brain\/awh203","journal-title":"Brain"},{"key":"12992_CR102","first-page":"1","volume":"10","author":"J Yuan","year":"2010","unstructured":"Yuan J, Page DB, Ku GY, Li Y, Mu Z, Ariyan C, Gallardo HF, Roman RA, Heine AI, Terzulli SL, Ritter E, Gnjatic S, Ritter G, Jungbluth AA, Allison JP, Old LJ, Wolchok JD (2010) Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immun 10:1","journal-title":"Cancer Immun"},{"key":"12992_CR103","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science 331:1565\u20131570. https:\/\/doi.org\/10.1126\/science.1203486","journal-title":"Science"},{"key":"12992_CR104","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ana.25708","volume":"87","author":"D Dubey","year":"2020","unstructured":"Dubey D, David WS, Reynolds KL, Chute DF, Clement NF, Cohen JV, Lawrence DP, Mooradian MJ, Sullivan RJ, Guidon AC (2020) Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol 87:659\u2013669. https:\/\/doi.org\/10.1002\/ana.25708","journal-title":"Ann Neurol"},{"key":"12992_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030546","author":"F Petrelli","year":"2020","unstructured":"Petrelli F, Signorelli D, Ghidini M, Ghidini A, Pizzutilo EG, Ruggieri L, Cabiddu M, Borgonovo K, Dognini G, Brighenti M, De Toma A, Rijavec E, Garassino MC, Grossi F, Tomasello G (2020) Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12030546","journal-title":"Cancers (Basel)"},{"key":"12992_CR106","doi-asserted-by":"publisher","first-page":"e2472","DOI":"10.1212\/wnl.0000000000207632","volume":"101","author":"J Pepys","year":"2023","unstructured":"Pepys J, Stoff R, Ramon-Gonen R, Ben-Betzalel G, Grynberg S, Frommer RS, Schachter J, Asher N, Taliansky A, Nikitin V, Dori A, Shelly S (2023) Incidence and outcome of neurologic immune-related adverse events associated with immune checkpoint inhibitors in patients with melanoma. Neurology 101:e2472\u2013e2482. https:\/\/doi.org\/10.1212\/wnl.0000000000207632","journal-title":"Neurology"},{"key":"12992_CR107","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","volume":"6","author":"C Dolladille","year":"2020","unstructured":"Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, Fedrizzi S, Chr\u00e9tien B, Da-Silva A, Plane AF, Legallois D, Milliez PU, Lelong-Boulouard V, Alexandre J (2020) Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol 6:865\u2013871. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0726","journal-title":"JAMA Oncol"},{"key":"12992_CR108","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s00415-021-10870-6","volume":"269","author":"A Vogrig","year":"2022","unstructured":"Vogrig A, Mu\u00f1iz-Castrillo S, Farina A, Honnorat J, Joubert B (2022) How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update. J Neurol 269:1701\u20131714. https:\/\/doi.org\/10.1007\/s00415-021-10870-6","journal-title":"J Neurol"},{"key":"12992_CR109","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/S1474-4422(23)00335-6","volume":"22","author":"E Fonseca","year":"2023","unstructured":"Fonseca E, Cabrera-Maqueda JM, Ruiz-Garc\u00eda R, Naranjo L, Diaz-Pedroche C, Velasco R, Macias-G\u00f3mez A, Milisenda JC, Mu\u00f1oz-Farjas E, Pascual-Go\u00f1i E, Perez-Larraya JG, Saiz A, Dalmau J, Blanco Y, Graus F, Martinez-Hernandez E, Aldecoa I, Barcelo MI, Canneti B, Cedres S, Chavarria A, Fabregat-Franco C, Ferrer-Civeira M, Frutos-Alegria MT, Guasp M, Landete L, Llufriu S, Marti MT, Martinez-Rodriguez JE, Matas-Garcia A, Moreno-Pulido S, Pelayo-Negro AL, Reig M, Riancho J, S\u00e1nchez-Vizca\u00edno C, Sanduzzi-Zamparelli M, Sepulveda M, Silvarrey-Rodriguez S, Tagliani P (2023) Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study. Lancet Neurol 22:1150\u20131159. https:\/\/doi.org\/10.1016\/S1474-4422(23)00335-6","journal-title":"Lancet Neurol"},{"key":"12992_CR110","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11060-020-03687-2","volume":"152","author":"T Mikami","year":"2021","unstructured":"Mikami T, Liaw B, Asada M, Niimura T, Zamami Y, Green-LaRoche D, Pai L, Levy M, Jeyapalan S (2021) Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database. J Neurooncol 152:135\u2013144. https:\/\/doi.org\/10.1007\/s11060-020-03687-2","journal-title":"J Neurooncol"},{"key":"12992_CR111","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jamaneurol.2021.0249","volume":"78","author":"R Velasco","year":"2021","unstructured":"Velasco R, Villagr\u00e1n M, Jov\u00e9 M, Sim\u00f3 M, Vilari\u00f1o N, Alemany M, Palmero R, Mart\u00ednez-Villacampa MM, Nadal E, Bruna J (2021) Encephalitis Induced by Immune Checkpoint Inhibitors: a Systematic Review. JAMA Neurol 78:864\u2013873. https:\/\/doi.org\/10.1001\/jamaneurol.2021.0249","journal-title":"JAMA Neurol"},{"key":"12992_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101011","volume":"44","author":"A Farina","year":"2024","unstructured":"Farina A, Villagr\u00e1n-Garc\u00eda M, Fourier A, Pinto AL, Chorfa F, Timestit N, Alberto T, Aupy J, Benaiteau M, Birzu C, Campetella L, Cotton F, Dalle S, Delaruelle CF, Dumez P, Germi R, Le Mar\u00e9chal M, Maillet D, Marignier R, Pegat A, Psimaras D, Rafiq M, Picard G, Desestret V, Quadrio I, Honnorat J, Joubert B (2024) Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study. Lancet Reg Health Eur 44:101011. https:\/\/doi.org\/10.1016\/j.lanepe.2024.101011","journal-title":"Lancet Reg Health Eur"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-12992-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-12992-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-12992-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T13:40:47Z","timestamp":1742218847000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-12992-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":112,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["12992"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-12992-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"249"}}